June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Comparative efficacy of bevacizumab and aflibercept in the rabbit DL-AAA model of chronic retinal neovascularization
Author Affiliations & Notes
  • Robertas Cesna
    Experimentica Ltd., Vilnius, Lithuania
  • Tomas Paulauskas
    Experimentica Ltd., Vilnius, Lithuania
  • Kernius Mickevicius
    Experimentica Ltd., Vilnius, Lithuania
  • Donatas Neverauskas
    Experimentica Ltd., Vilnius, Lithuania
  • Inesa Lelyte
    Experimentica Ltd., Vilnius, Lithuania
  • Simon Kaja
    Experimentica Ltd., Vilnius, Lithuania
    Departments of Ophthalmology and Molecular Pharmacology & Neuroscience, Loyola University, Maywood, Illinois, United States
  • Giedrius Kalesnykas
    Experimentica Ltd., Vilnius, Lithuania
  • Symantas Ragauskas
    Experimentica Ltd., Vilnius, Lithuania
  • Footnotes
    Commercial Relationships   Robertas Cesna, Experimentica ltd. (F), Experimentica ltd. (E); Tomas Paulauskas, Experimentica ltd. (F), Experimentica ltd. (E); Kernius Mickevicius, Experimentica ltd. (F), Experimentica ltd. (E); Donatas Neverauskas, Experimentica ltd. (F), Experimentica ltd. (E); Inesa Lelyte, Experimentica ltd. (F), Experimentica ltd. (E); Simon Kaja, Experimentica ltd. (F), Experimentica ltd. (I), Experimentica ltd. (E), Experimentica ltd. (P), Experimentica ltd. (R), Experimentica ltd. (S), K&P Scientific LLC (F), K&P Scientific LLC (I), K&P Scientific LLC (C), K&P Scientific LLC (P), K&P Scientific LLC (R), K&P Scientific LLC (S); Giedrius Kalesnykas, Experimentica Ltd. (F), Experimentica Ltd. (I), Experimentica Ltd. (E), Experimentica Ltd. (P), Experimentica Ltd. (R), Experimentica Ltd. (S), Spouse - Experimentica Ltd. (I), Spouse - Experimentica Ltd. (S); Symantas Ragauskas, Experimentica ltd. (F), Experimentica ltd. (I), Experimentica ltd. (E), Experimentica ltd. (P), Experimentica ltd. (R), Experimentica ltd. (S)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 5391. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Robertas Cesna, Tomas Paulauskas, Kernius Mickevicius, Donatas Neverauskas, Inesa Lelyte, Simon Kaja, Giedrius Kalesnykas, Symantas Ragauskas; Comparative efficacy of bevacizumab and aflibercept in the rabbit DL-AAA model of chronic retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2020;61(7):5391.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intravitreal administration of DL-α-aminoadipic acid (DL-AAA) induces chronic retinal neovascularization (RNV). Here we compared efficacy of biosimilar bevacizumab and aflibercept against RNV induced by DL-AAA in Dutch Belted rabbits.

Methods : Adult Dutch-Belted rabbits (DB) were selected, randomized and sorted into 3 treatment groups: DL-AAA followed by 1) intravitreal (IVT) administration of aflibercept at a dose of 250 µg/eye, 2) IVT administration of bevacizumab at a dose of 1 250 µg/eye, and 3) IVT administration of saline.
The animals were monitored prior to RNV induction and during the whole 21 week follow-up period post-induction using in vivo imaging, spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA). RNV was induced in DB rabbits by intravitreal injections of DL-AAA. DL-AAA-characteristics changes of RNV were monitored using in vivo imaging at 1 week post- injection and every 2 weeks at later time points. At 13 weeks post-induction bevacizumab, aflibercept or saline were intravitreally injected. The animals were followed for the additional 8 weeks.

Results : The RNV-associated leakage was detected already on the first week in all DB rabbits that received DL-AAA injection. The mean leakage area was 41.9 µm 2 ± 20.9 µm2. At weeks 5-7 post-induction the RNV leakage peaked to 56.9 µm2 ± 25.6 µm2 and remained unchanged until week 13. Intravitreal administration of bevacizumab decreased the leakage area by 11.4 µm2 ± 8.6 µm2 and aflibercept treatment decreased the leakage area by 7.2 µm2 ± 5 µm2 at 2 weeks post-treatment administration as compared to saline-treated eyes.
At later time points the RNV leak again increased to 30.2 µm2 ± 7.4 µm2 in the aflibercept group and to 61.9 µm2 ± 23.6 µm2 in the bevacizumab group. The saline/treated eyes had a leakage of 56.7 µm2 ± 12.5 µm2.

Conclusions : Both bevacizumab and aflibercept significantly decreased the leakage area after intravitreal administration equally well. However, in a long term aflibercept was more efficacious to decrease RNV leak as compared to bevacizumab.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×